Welcome to our dedicated page for FARADAY FUTURE INTELLIGENT ELECTRIC SEC filings (Ticker: FFAI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Faraday Future Intelligent Electric Inc. filings document the public-company disclosures of an electric vehicle and Embodied AI company with Class A common stock and redeemable warrants listed on Nasdaq. Its regulatory record includes material-event reports, proxy materials, operating and financial results, and governance disclosures.
Recent filings cover material definitive agreements, secured promissory notes, loan and securities purchase arrangements, preferred stock matters, executive and board changes, shareholder meeting proposals, director elections, Nasdaq share-issuance approvals, risk factors, capital structure, and securities registered for trading under the FFAI and FFAIW symbols.
Faraday Future Intelligent Electric Inc. filed an 8-K under Item 8.01 to furnish a press release about the final launch event for its FX Super One. The event is scheduled to take place in Dubai, UAE on October 28, 2025.
The company stated the information is being furnished and not deemed filed under the Exchange Act. The filing includes Exhibit 99.1 (Press Release dated October 15, 2025) and the cover page interactive data file.
Faraday Future Intelligent Electric Inc. filed a current report to note that it has closed an investment in Qualigen Therapeutics, Inc., a company listed on Nasdaq under the symbol QLGN. The closing occurred on September 30, 2025, and was announced the same day in a press release.
The report classifies this as an "Other Events" disclosure and includes the press release as an exhibit. No financial terms or strategic details of the investment are described in the excerpt, but the filing confirms that the transaction has been completed rather than merely planned.
Faraday Future Intelligent Electric Inc. reported a planned strategic investment in Qualigen Therapeutics. On September 19, 2025, the company agreed to invest approximately $40.7 million, payable in cash, USDC stablecoin or other cryptocurrencies, to purchase Qualigen common stock at $2.246 per share and/or Series B preferred stock at $1,000 per share. At closing, Faraday Future will gain the right to designate multiple Qualigen directors, including the board chair, and have its designees appointed as Co‑CEO and CFO of Qualigen.
Qualigen must file a resale registration statement for the purchased securities within 45 days and seek stockholder approval by late October 2025 or November 2025, with repeated meetings required until approval is obtained. Separately, Faraday Future shareholders approved amendments increasing authorized common stock from 167,245,313 to 232,470,985 shares and authorized preferred stock from 12,900,000 to 17,931,000 shares, and added 9,500,000 shares to the 2021 stock incentive plan, while rejecting a proposed name change.